Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nycomed submits ultrasound agent to FDA:

This article was originally published in Clinica

Executive Summary

Nycomed Amersham Imaging has submitted its Sonazoid ultrasound contrast agent to the US FDA for approval. The new drug application included data from 1,300 patients in US and European trials and the company will submit an application for European approval later this year. Sonazoid is for heart and liver applications and Nycomed is also investigating its use in myocardial perfusion imaging. Daiichi Pharmaceutical, Nycomed's Japanese partner in ultrasound, has completed Phase I trials for Sonazoid in that country.

You may also be interested in...



Majority Of Spanish OTC Firms Investing Heavily In Digital

A recent ANEFP survey shows that the majority of Spanish OTC firms consider their digital strategies to be "very advanced."

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

Topics

UsernamePublicRestriction

Register

MT079190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel